Search Results - Suzanne Travers
- Showing 1 - 4 results of 4
-
1
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease by Stephen B. Hanauer, Carrie Wagner, Mohan Bala, Lloyd Mayer, Suzanne Travers, Robert H. Diamond, Allan Olson, Warren Bao, Paul Rutgeerts
Published 2004Artigo -
2
Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn’s Disease in Children by Jeffrey S. Hyams, Wallace Crandall, Subra Kugathasan, Anne M. Griffiths, Allan Olson, Jewel Johanns, Grace Liu, Suzanne Travers, Robert Heuschkel, James Markowitz, Stanley A. Cohen, Harland S. Winter, G. Veereman‐Wauters, George D. Ferry, Robert N. Baldassano
Published 2006Artigo -
3
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis by Paul Rutgeerts, William J. Sandborn, Brian G. Feagan, Walter Reinisch, Allan Olson, Jewel Johanns, Suzanne Travers, Daniel Rachmilewitz, Stephen B. Hanauer, Gary R. Lichtenstein, Willem J.S. de Villiers, Daniel H. Present, Bruce E. Sands, Jean‐Frédéric Colombel
Published 2005Artigo -
4
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease by Bruce E. Sands, Frank Anderson, Çharles N. Bernstein, William Y. Chey, Brian G. Feagan, Richard N. Fedorak, Michael A. Kamm, Joshua R. Korzenik, Bret A. Lashner, Jane E. Onken, Daniel Rachmilewitz, Paul Rutgeerts, Gary Wild, Douglas C. Wolf, P Marsters, Suzanne Travers, Marion Blank, S J van Deventer
Published 2004Artigo
Search Tools:
Related Subjects
Disease
Gastroenterology
Infliximab
Internal medicine
Medicine
Surgery
Alternative medicine
Chemotherapy
Crohn's disease
Maintenance therapy
Pathology
Placebo
Randomized controlled trial
Antibody
Confidence interval
Environmental health
Immunology
Incidence (geometry)
Inflammatory bowel disease
Optics
Physics
Population
Randomization
Regimen
Tumor necrosis factor alpha
Ulcerative colitis